
Aclaris Bosakitug Misses Primary Endpoint in Dermatitis
Aclaris Therapeutics reported Phase 2 ADMIRATION trial results for its anti-TSLP antibody bosakitug in moderate-to-severe atopic dermatitis.

Aclaris Therapeutics reported Phase 2 ADMIRATION trial results for its anti-TSLP antibody bosakitug in moderate-to-severe atopic dermatitis.